title: Proteomic technologies for cancer target validation.
abstract: Genomic and proteomic technologies have produced an abundance of drug targets, which is creating a bottleneck in drug development process. There is an increasing need for better target validation for cancer drug development and proteomic technologies are contributing to it. These technologies are compared to enable the selection of the one by matching the needs of a particular project. There are prospects for further improvement, and proteomics technologies will form an important addition to the existing genomic and chemical technologies for target validation.
authors: Jain PharmaBiotech, Blaesiring 7, 4057 Basel, Switzerland. Electronic address:http://pharmabiotech.ch.
authors: K K
authors: KK
authors: Jain